Abstract
吴晓亮,叶兆嘉,谢旭,黄芳,孔东锋,冯铁建,张顺祥,蒋亚文.基于马尔科夫模型的深圳市60岁及以上人群接种流感疫苗的成本效果分析[J].Chinese journal of Epidemiology,2022,43(7):1140-1146
基于马尔科夫模型的深圳市60岁及以上人群接种流感疫苗的成本效果分析
Based on a Markov model, cost-effectiveness analysis of influenza vaccination among people aged 60 years and older in Shenzhen
Received:December 21, 2021  
DOI:10.3760/cma.j.cn112338-20211221-01005
KeyWord: 流感疫苗  成本效果分析  马尔科夫状态转换模型
English Key Word: Influenza vaccine  Cost-effectiveness analysis  Markov state transition model
FundProject:中华预防医学会慢性病与免疫预防政策研究(预会协议628)
Author NameAffiliationE-mail
Wu Xiaoliang Shenzhen Center for Disease Control and Prevention, Shenzhen 518073, China  
Ye Zhaojia Shenzhen Center for Disease Control and Prevention, Shenzhen 518073, China yzj228@126.com 
Xie Xu Shenzhen Center for Disease Control and Prevention, Shenzhen 518073, China  
Huang Fang Shenzhen Center for Disease Control and Prevention, Shenzhen 518073, China  
Kong Dongfeng Shenzhen Center for Disease Control and Prevention, Shenzhen 518073, China  
Feng Tiejian Shenzhen Center for Disease Control and Prevention, Shenzhen 518073, China  
Zhang Shunxiang Shenzhen Center for Disease Control and Prevention, Shenzhen 518073, China  
Jiang Yawen School of Public Health, Sun Yat-sen University (Shenzhen), Shenzhen 518107, China  
Hits: 3334
Download times: 830
Abstract:
      目的 评估深圳市≥60岁人群免费接种流感疫苗的成本效果。方法 以深圳市≥60岁常住人群为研究对象,构建马尔科夫状态转换模型,从社会的角度来评估与不接种疫苗相比,每年接种流感疫苗预防流感的成本效果。模型以周为周期,研究时限5年,模拟流感发病的季节性变化。采用5%的年贴现率对模型中的成本和质量调整生命年(QALYs)进行贴现并计算净货币效益(NMB),以2019年中国人均国内生产总值GDP(70 892元)作为支付意愿阈值进行评价。单因素和概率敏感性分析用于评估参数不确定性对结果的影响。结果 与不接种疫苗相比,人均节约总成本35元并且多获得0.007个QALYs,人均获得的NMB为529元。单因素敏感性分析的结果显示,流感发病率和流感疫苗保护效果是影响基线结果的主要因素。在1 000次的蒙特卡罗模拟中,接种流感疫苗具有成本效果的概率为100%。结论 与不接种疫苗相比,深圳市≥60岁人群每年接种流感疫苗是一项成本节约的疾病预防策略。
English Abstract:
      Objective To assess the cost-effectiveness of influenza vaccination among people aged 60 years and older in Shenzhen. Methods A Markov state transition model was constructed to evaluate the cost-effectiveness of annual influenza vaccination for preventing influenza infection compared with no vaccination among the elderly from the social perspective. Allowing seasonal variation of influenza activity, the model followed a five-year cohort using weekly cycles. We employed once the Chinese gross domestic product (GDP) per capita in 2019 (70 892 yuan) as the willingness-to-pay (WTP) threshold and calculated the net monetary benefit (NMB) with costs and quality-adjusted life-years (QALYs) discounted at 5% annually. The impact of parameter uncertainty on the results was examined using one-way and probabilistic sensitivity analyses (PSA). Results The base case amounted to approximately 35 yuan of cost-saving and a net gain of 0.007 QALYs. Correspondingly, the NMB was 529 yuan per vaccinated person. One-way sensitivity analyses showed that the NMB was relatively sensitive to changes in the attack rate of influenza and vaccine effectiveness. Based on the results of PSA with 1 000 Monte Carlo simulations, influenza vaccination had a probability of being cost-effective in 100% of the repetitions.Conclusions The present study provides evidence that influenza vaccination is a cost-saving disease prevention strategy for people aged 60 years and older in Shenzhen.
View Fulltext   Html FullText     View/Add Comment  Download reader
Close